

Monika Twarogowska (1), Géraldine Ayrat (1), Pauline Traynard (1), Jonathan Chauvin (1)

(1) Lixoft, Antony, France. Contact: jonathan.chauvin@lixoft.com

Want to know "What's new" in 2020 release?




## INTRODUCTION

### Simulx – GUI 2020

- Advanced **simulator** of clinical trials and **decision-making** tool
- Easy-to-use and interactive **interface**
- Intuitive** workflow
- Interconnected** with MonolixSuite applications
- Flexible** in building simulation scenarios
- Advanced computational capabilities with **C++ engine**
- Immediate **visual feedback**
- Export** of plots and results

### How does it work?



EXPLORATION



SIMULATION

DEFINITION

### Example

**Remifentanyl PKPD dataset** - opioid analgesic drug used for sedation tested on 65 healthy adults who received an infusion at different rates; *concentration of the drug and EEG measurements*


### Clinical study questions:

- What percentage of individuals reach the efficacy target at different dose levels?
- What is the uncertainty of the result in a small size trial and how does it change if more individuals are recruited?

### Methods:

**Model:** PKPD model from the Monolix library with the population parameters estimated in Monolix


**Simulations:** qualitative and quantitative comparison of two arms with different treatments and different number of subjects



## DEFINITION & EXPLORATION

### Import from Monolix

Starting a Simulx project from a Monolix project loads automatically the model developed in Monolix and creates all simulation elements with values estimated by Monolix or read from a dataset.




### Definition of simulation elements

Creating new simulation elements is very flexible using single values, regular grids, distributions or external files.


### New treatment elements:

- Infusion for 2h with different infusion rates: 25 or 50  $\mu\text{g}/\text{min}$
- Definition of the infusion starting time, the dose amount and the infusion duration
- Other options: cycles, covariate scaling, non-compliance probability



### Exploration

Exploration tab allows to simulate a typical individual to investigate different treatments and effects of model parameters.




## SIMULATION

### Simulation of a clinical trial with two treatments

The Simulation tab aim is to simulate populations of individuals in groups, either one or several. It contains a simulation scenario builder which uses simulation elements defined in the "Definition" tab.


- Four groups** with different treatments (25 or 50  $\mu\text{m}/\text{min}$  infusion rate) and different number of individuals (20 or 100)
- Individual parameters** simulated using population parameters estimated by Monolix and covariates from the original dataset
- Output:** model predictions for the concentration and EEG
- Several simulations of the scenario (**replicates**) for uncertainty assessment



### Efficacy target


The Outcomes & Endpoints task is used for post-processing of the simulation outputs. Several outcomes can be combined into an endpoint, and several endpoints can be created. Statistical tests compare endpoints between groups.

- Outcome:** EEG at time 120 min in the EEG target range [5, 15] Hz
- Efficacy endpoint:** percentage of individuals in the EEG target
- Stat test:** Fisher's exact test for the odds ratio between test groups and reference group




## PLOTS & RESULTS


**Individual output**  
Concentration vs time with the mean and sd.




**Output distribution**  
EEG vs time with the efficacy target limits



**Outcome distribution**  
Number of individuals in and outside the efficacy target




**Endpoint distribution**  
Distribution of the percentage of individuals in the efficacy target



### Results

Tables display the percentage of individuals in the EEG target for each replicates. With 20 individuals per arm, this percentage varies from 20 to 65 for the 25 $\mu\text{m}/\text{min}$  arm and from 50 to 95 for the 50 $\mu\text{m}/\text{min}$  arm. The difference between arms is significant: 36% over the clinical trial replicates. With 100 individuals per arm, the probability of success is 76% for the 50 $\mu\text{m}/\text{min}$  arm.



[www.simulx.lixoft.com](http://www.simulx.lixoft.com)